All In Biotech

Drug Trial Radar · NCT06947109

A Clinical Study of AK139 in Healthy Subjects

A Phase I Clinical Study on Dose Escalation Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of AK139 in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

Jan 30, 2026

Study completion Jan 30, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I clinical study on dose escalation evaluating the safety, tolerability, PK and PD of a single dose of AK139 administered subcutaneously in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

  • PlaceboDrug

    Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.

  • AK111Drug

    The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AE)Time frame: Baseline to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Xiaoshan Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.